Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miglitol to preparation of medicine for treating cardiovascular diseases

A miglitol, cardiovascular technology, applied in the field of medicine, can solve the problems of difficult disease cure, complex ventricular morphological remodeling, etc.

Pending Publication Date: 2020-06-30
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In conclusion, the pathogenesis of heart failure involves complex morphological remodeling of the ventricle, and the current methods used in the actual treatment process are difficult to cure the disease, so it is urgent to develop new drugs for the treatment of heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miglitol to preparation of medicine for treating cardiovascular diseases
  • Application of miglitol to preparation of medicine for treating cardiovascular diseases
  • Application of miglitol to preparation of medicine for treating cardiovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1. Materials and methods

[0027] 1.1 Experimental animals

[0028] Seventy-five 8-week-old SPF male SD rats were purchased from the Experimental Animal Center of Peking University Health Science Center (permit number: SCXK (Beijing) 2016-0001), weighing 220-260 g. They were adaptively fed for one week in an animal room with a temperature of 24-26°C, a humidity of 50%-65%, and 12 hours of day and night alternation, during which time they were free to move and eat.

[0029] 1.2 Modeling and grouping

[0030] 15 out of 75 SD rats were taken as a sham operation group, and the other rats were referred to the method of narrowing the abdominal aorta to prepare the CHF rat model: the rats were anesthetized by intraperitoneal injection of 3% pentobarbital sodium (40mg / kg) , cut the skin at 2-3 cm in the middle of the lower abdomen under the xiphoid process, open the abdominal cavity, separate the abdominal aorta, place a No. 7 surgical needle parallel to the abdominal aorta, ...

Embodiment 2

[0060] Embodiment 2 miglitol tablet

[0061] formula:

[0062]

[0063] Preparation process: Accurately weigh and mix Miglitol and mannitol in the formula, gradually add low-substituted hydroxypropyl cellulose and croscarmellose sodium, and finally add microcrystalline cellulose and silica gel to the mixture to strengthen the main body. To improve the fluidity of the medicine and prevent the sticking during the tableting process, the main medicine and the auxiliary materials are completely mixed and then pressed into the tablet, that is to say.

Embodiment 3

[0064] Embodiment 3 miglitol composition tablet

[0065]

[0066]

[0067] Preparation process: Accurately weigh and mix Miglitol and mannitol in the formula, gradually add low-substituted hydroxypropyl cellulose and croscarmellose sodium, and finally add microcrystalline cellulose and silica gel to the mixture to strengthen the main body. To improve the fluidity of the medicine and prevent the sticking during the tableting process, the main medicine and the auxiliary materials are completely mixed and then pressed into the tablet, that is to say.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an application of miglitol to preparation of a medicine for treating cardiovascular diseases, and belongs to the technical field of medicines. The medicine is a medicament prepared from the miglitol as an active ingredient and a pharmaceutically acceptable excipient, and the obtained medicament has the remarkable treatment effect on the cardiovascular diseases caused by myocardial cell autophagy. Pharmacological tests show that the miglitol can obviously improve cardiac function injury and myocardial cell necrosis, improves the expression level of LC3 protein, and is suitable for being widely applied to treatment of the cardiovascular diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of miglitol in the preparation of drugs for treating cardiovascular diseases. Background technique [0002] Miglitol (miglitol) is an oral hypoglycemic drug developed by Bayer in the 1980s. Its structure is similar to that of glucose. The decomposition and absorption of monosaccharides and other monosaccharides in the upper part of the small intestine can reduce the blood sugar level after meals. It effectively alleviates postprandial hyperglycemia and the sharp changes in blood sugar after meals in diabetic patients, and has less side effects, and its remarkable curative effect has been unanimously recognized by diabetic patients. [0003] Heart failure (heart failure) referred to as heart failure refers to the failure of the venous blood to fully discharge the heart due to the dysfunction of the systolic function and / or diastolic function of the heart, res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/445A61P9/00A61P9/04A61P9/10A61P9/06
CPCA61K31/445A61P9/00A61P9/04A61P9/10A61P9/06
Inventor 孙成磊宋毅支运霞
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com